Page last updated: 2024-09-04

ezetimibe and Hyperlipoproteinemia Type II

ezetimibe has been researched along with Hyperlipoproteinemia Type II in 135 studies

Research

Studies (135)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	41 (30.37)	29.6817
2010's	71 (52.59)	24.3611
2020's	23 (17.04)	2.80

Authors

Authors	Studies
Anastassopoulou, A; Barrios, V; Carter, AM; Soronen, J	1
Agapakis, D; Anagnostis, P; Antza, C; Attilakos, A; Dima, I; Doumas, M; Garoufi, A; Kiouri, E; Kolovou, G; Kotsis, V; Lambadiari, V; Liberopoulos, EN; Rallidis, L; Rizos, CV; Sfikas, G; Skalidis, E; Skoumas, I; Tziomalos, K; Vlachopoulos, C; Zacharis, E	1
Chen, S; Du, Y; Li, Q; Liu, Q; Tan, C; Wang, QK; Wu, C; Xu, C; Yang, H; Zhang, H; Zhang, X; Zhu, Q	1
Choi, SH; Jeong, IK; Kang, HJ; Kim, BJ; Lee, CJ; Lee, SH; Yoon, M	1
Hande, LN; Hansen, SH; Hov, JR; Hovland, A; Kummen, M; Lappegård, KT; Storm-Larsen, C; Thunhaug, H; Trøseid, M; Vestad, B	1
Bartuli, A; Bergeron, J; Bhatia, AK; Buonuomo, PS; Descamps, OS; Gaudet, D; Greber-Platzer, S; Hovingh, GK; Kastelein, JJP; Luirink, I; Mach, F; Raal, FJ; Ruzza, A; Santos, RD; Stefanutti, C; Wang, B; Wiegman, A	1
Agarwala, R; Bansal, M; Bordoloi, N; Chag, M; Chakraborty, R; Duell, PB; Iyengar, SS; Kalra, D; Kapoor, D; Kasliwal, R; Khan, A; Khanna, NN; Mahajan, K; Manoria, PC; Mehrotra, R; Mehta, A; Mehta, V; Melinker, RP; Mukhopadhyay, S; Muruganathan, A; Nanda, R; Narasingan, SN; Pancholia, AK; Pareek, KK; Prabhakar, D; Pradhan, A; Puri, R; Rastogi, A; Saboo, B; Sattur, GB; Sheikh, A; Shetty, S; Soumitra, K; Tiwaskar, MH; Wangnoo, SK; Wong, ND; Yusuf, J	1
Chua, YA; Ibrahim, KS; Kasim, SS; Md Radzi, AB; Mohd Kasim, NA; Nawawi, H; Nazli, SA; Rosman, A	1
Boersma, E; Bogsrud, MP; Hamkour, S; Holven, KB; Imholz, B; Johansen, AK; Koopal, C; Louters, L; Retterstøl, K; Roeters van Lennep, JE; Schreuder, MM; Siegers, KE; van de Ree, MA; Visseren, FLJ	1
Chauhan, A; Gu, J; Kuznik, A; Quon, P; Raal, FJ; Sravya, TS	1
Bakker-Arkema, R; Bisgaier, C; Durst, R; Gaudet, D; Golden, L; Hegele, RA; Kastelein, JJ; Lepor, N; Masson, L; Stein, E	1
Choksi, RR; Goldfaden, RF; Lewis, T; Niman, S; Rana, K; Reid, J; Sheikh-Ali, M	1
Hovingh, GK; Kallend, D; Lepor, NE; Raal, FJ; Stoekenbroek, RM; Wijngaard, PLJ	1
Dateki, S; Ikeda, K; Kashimada, K; Komiya, C; Mishima, H; Nakano, Y; Ogawa, Y; Shiba, K; Shimizu, H; Tsujimoto, K; Yamada, T; Yoshiura, KI	1
Walsh, CM	1
Piszczatoski, C; Powell, J	1
Di Mauro, S; Di Pino, A; Ferrara, V; Filippello, A; Marchisello, S; Piro, S; Purrello, F; Rabuazzo, AM; Scamporrino, A; Scicali, R; Urbano, F	1
Benaiges, D; Brea-Hernando, Á; Civeira, F; Climent, E; Lafuente, H; Marco-Benedí, V; Ortega-Martínez de Victoria, E; Pedro-Botet, J; Pintó, X; Plana, N; Suárez-Tembra, M; Vila, À	1
Di Pino, A; Ferrara, V; Piro, S; Purrello, F; Rabuazzo, AM; Scicali, R	1
Cohen, H; Stefanutti, C	1
Arai, H; Bujo, H; Daida, H; Harada-Shiba, M; Ishibashi, S; Koga, N; Masuda, D; Oikawa, S; Yamashita, S	1
Bell, DA; Brett, T; Chow, CK; Hare, DL; Horton, AE; Justo, RN; Kostner, KM; Martin, AC; Pang, J; Poplawski, NK; Srinivasan, S; Sullivan, DR; Trent, RJ; Watts, GF	1
Al-Allaf, FA; Al-Jarallah, M; Al-Rasadi, K; Al-Waili, K; Al-Zakwani, I; Alghamdi, M; Alhabib, KF; Almahmeed, W; Almigbal, TH; Alnouri, F; AlQudaimi, A; AlSarraf, A; AlSayed, N; Altaradi, H; Amin, H; Atallah, B; Awan, Z; Batais, MA; Kinsara, AJ; Sabbour, H; Traina, M; Zadjali, F	1
Arca, M; Barale, C; Baratta, F; Bartimoccia, S; Cammisotto, V; Carnevale, R; Castellani, V; Cocomello, N; D'Erasmo, L; Del Ben, M; Di Pino, A; Nocella, C; Pastori, D; Pignatelli, P; Piro, S; Purrello, F; Russo, I; Scicali, R; Violi, F	1
De Simone, B; Di Taranto, MD; Fortunato, G; Gentile, M; Giacobbe, C; Iannuzzi, A; Iannuzzo, G; Jossa, F; Marotta, G; Rubba, P; Sodano, M	1
Al Kindi, M; Al Rasadi, K; Al Waili, K; Aljenedil, S; Awan, Z; Bélanger, AM; Genest, J; Ruel, I; Sayegh, K; Senouci, S; Sivakumaran, L; Valenti, D	1
Civeira, F; Ibarretxe, D; Lamiquiz-Moneo, I; Masana, L; Ortega, E; Pedro-Botet, J; Pérez-Calahorra, S; Plana, N; Suárez-Tembra, M; Valdivielso, P	1
Ako, J; Arai, H; Harada-Shiba, M; Hirayama, A; Nakamura, M; Nohara, A; Uno, K	1
Flugelman, MY; Halon, DA; Jubran, A; Lavie, G; Shapira, C; Zafrir, B	1
Aljenedil, S; Baass, A; Bergeron, J; Brisson, D; Brophy, JM; Brunham, LR; Cermakova, L; Couture, P; de Varennes, É; Dufour, R; Francis, GA; Gaudet, D; Genest, J; Hegele, RA; Mancini, GBJ; Ruel, I; Ryomoto, A; Sadri, I; Wanneh, E	1
Di Giacomo, S; Mazza, F; Mesce, D; Morozzi, C; Pergolini, M; Stefanutti, C; Vitale, M	1
Aggarwal, J; Boatman, B; Harrison, DJ; Menzin, J; Patel, JG; Stern, K; Yu, J	1
Blanchard, V; Blom, DJ; Bourane, S; Cariou, B; Chemello, K; Croyal, M; Farnier, M; Lambert, G; Nativel, B; Pichelin, M; Raal, FJ; Ramin-Mangata, S; Tang, L; Thedrez, A	1
Boklage, SH; Elassal, J; Ghannam, AF; Gupta, R; Karalis, DG; Mallya, UG	1
Doyle, M; Moss, S; Rees, D; Tardo, D	1
Baum, SJ; Brown, AS	1
Bálinth, K; Bugáňová, I; Fábryová, Ľ; Kadurová, M; Klabník, A; Kozárová, M; Rašlová, K; Sirotiaková, J; Vohnout, B	1
Barron, JK; Blom, DJ; Brice, BC; Huijgen, R; Marais, AD; van Delden, XM; Wolmarans, KH	1
Blaha, V; Freiberger, T; Kyselak, O; Maskova, J; Raslová, K; Satny, M; Soska, V; Urbanek, R; Vaclova, M; Vohnout, B; Vrablik, M	1
Catapano, AL; Hovingh, GK; Raal, FJ	1
Abdullaeva, G; Alieva, R; Hoshimov, S; Kurbanov, R; Nagay, A; Nizamov, U; Shek, A	1
Maliachova, O; Stabouli, S	1
Kuang, H; Li, L; Lu, T; Shou, W; Yi, Q; Zhou, X	1
Addison, J; Kitova, LG; Lachev, VI; Petkova, RT; Petrov, IS; Postadzhiyan, AS; Tokmakova, MP; Tsonev, SN	1
Bärlocher, A; Bilz, S; Brändle, M; Gerth, Y; Korte, W; Müller, P; Rickli, H; Schöb, M	1
Chitose, T; Fujisue, K; Harada-Shiba, M; Hokimoto, S; Hori, M; Izumiya, Y; Kaikita, K; Kajiwara, I; Nagamatsu, S; Ogawa, H; Ono, T; Sakamoto, K; Shirahama, R; Sueta, D; Takashio, S; Tsujita, K; Yamamoto, E	1
Bea, AM; Cenarro, A; Civeira, F; Jarauta, E; Lamiquiz-Moneo, I; Marco-Benedí, V; Martín, C; Mateo-Gallego, R; Pérez-Calahorra, S	1
Hovingh, GK; Ray, KK; Reeskamp, LF	1
Davidson, M	1
Bajnok, L	1
Jannes, CE; Krieger, JE; Morgan, AC; Pereira, AC; Santos, PC; Santos, RD; Turolla, L	1
Aukrust, P; Halvorsen, B; Holven, KB; Langslet, G; Lindvig, HW; Narverud, I; Nenseter, MS; Ose, L; Retterstøl, K; Ulven, SM	1
Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM	1
Güleç, S; Özcan, ÖU	1
Emery, M; Langslet, G; Wasserman, SM	1
Dai, H; Lin, M; Zhao, S	1
Besseling, J; Kastelein, JJ; Sjouke, B	1
Al-Allaf, F; Al-Ashwal, A; Al-Mahfouz, A; Al-Rasadi, K; Al-Sayed, N; Al-Waili, K; Alnouri, F; Banerjee, Y; Genest, J; Razzaghy-Azar, M; Sabbour, H; Santos, RD	1
Beitel, LK; Chalifour, LE; Chowdhury, SF; Davis, H; Gottlieb, B; Makhoul, S; Paliouras, M; Schweitzer, M; Trifiro, M; Wang, E; Zaman, NM	1
Hegele, RA	1
Alonso, R; Badimón, L; Barba-Romero, MA; de Andrés, R; Diaz-Diaz, JL; Fuentes, F; Martinez-Faedo, C; Mata, N; Mata, P; Miramontes-Gonzalez, JP; Muñiz, O; Perez de Isla, L; Rubio-Marin, P; Saenz, P; Saltijeral Cerezo, A; Sanchez Muñoz-Torrero, JF; Watts, GF; Zambón, D	1
Ajufo, E; Rader, DJ	1
Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Miyashita, K; Nakajima, K; Nohara, A; Tada, H; Yamagishi, M	1
Diekmann, J; Farr, M; Horstkotte, D; Mellwig, KP; van Buuren, F	1
Krähenbühl, S; Pavik-Mezzour, I; von Eckardstein, A	1
Karádi, I; Paragh, G	1
Anderson, ML; Blasi, PR; Dunn, J; Henrikson, NB; Lozano, P; Morrison, CC; Nguyen, M; Whitlock, EP	1
Bibbins-Domingo, K; Coxson, PG; Guzman, D; Kazi, DS; Moran, AE; Ollendorf, DA; Pearson, SD; Penko, J; Tice, JA	1
Barrett, PH; Burnett, JR; Chan, DC; Mori, TA; Pang, J; Sullivan, DR; van Bockxmeer, FM; Watts, GF	1
Araujo, MB; Pacce, MS	1
Andisik, M; Bergeron, J; Dufour, R; Gaudet, D; Gipe, DA; Hovingh, GK; Pordy, R; Qing, Z; Torri, A; Weiss, R; Yang, F	1
Akdim, F; Gaudet, D; Kastelein, JJ	1
Michałek, A	1
Brown, WV; Harrison, DG; Raggi, P	1
Steinberg, D	1
Bybee, KA; Lavie, CJ; O'Keefe, JH	1
Eichhorn, EJ	1
Diamond, GA; Kaul, S	1
Connor, WE	1
Blake, JA	1
Kaye, T	1
Davis, HR; Graziano, MP; Murgolo, NJ	1
Berthold, HK; Nitschmann, S	1
Krasuski, RA	1
Avis, HJ; Cuffie-Jackson, C; Gagné, C; Kastelein, JJ; Shi, G; Trip, MD; van der Graaf, A; Veltri, E; Vissers, MN	1
Spence, JD	1
Farmer, JA	1
Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A	1
Benjannet, S; Bernier, L; Boulet, L; Davignon, J; Dubuc, G; Genest, J; Hamelin, J; Jacques, H; Paré, G; Seidah, NG; Tremblay, M	1
de Lorgeril, M	1
Davignon, J; Dubuc, G	1
Abbink, EJ; Huijgen, R; Imholz, BP; Kastelein, JJ; Liem, AH; Pijlman, AH; Stalenhoef, AF; Verhagen, SN; Visseren, FL	1
Groen, AK; Hutten, BA; Jakulj, L; Kastelein, JJ; Lutjohann, D; Veltri, EP; Vissers, MN	1
Calvert, NW; Demott, K; Humphries, SE; Minhas, R; Neil, HA; Nherera, L; Thorogood, M	1
Abbink, EJ; Bruckert, E; Durrington, PN; Eriksson, M; Huijgen, R; Imholz, BP; Kastelein, JJ; Schaefer, JR; Stalenhoef, AF; Trip, MD; Visseren, FL	1
Florkowski, CM; George, PM; King, RI; Laurie, AD; Reid, N; Scott, RS	1
Friedrich, DA	1
Colquhoun, D; Hamilton-Craig, I; Kostner, K; Woodhouse, S	1
Doggrell, SA	1
Elis, A; Stein, EA; Zhou, R	1
Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI	1
Justo, RN	1
Fujino, N; Hayashi, K; Inazu, A; Kawashiri, MA; Kobayashi, J; Konno, T; Mabuchi, H; Mori, M; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Yamagishi, M	1
Araujo, MB; Botto, PM; Mazza, CS	1
Floré, M; Hermans, H; Robberecht, N	1
Sijbrands, EJ	1
Bergeron, J; Dufour, R; Gaudet, D; Gipe, D; Pordy, R; Stein, EA; Weiss, R; Wu, R	1
Chadli, A; El Aziz, S; El Ghomari, H; Farouqi, A	1
Colotto, M; Durante, C; Renzi, A	1
Bridges, I; Li, G; Raal, F; Scott, R; Somaratne, R; Stein, EA; Wasserman, SM	1
Al-Abri, A; Al-Dhuhli, H; Al-Hashmi, K; Al-Hinai, AT; Al-Rasadi, K; Al-Sabti, H; Al-Waili, K; Al-Yaarubi, S; Al-Zakwani, I; Banerjee, Y	1
Coakley, J; Forbes, DA; Martin, AC; Sullivan, DR; Watts, GF	1
Bossenmayer, S	1
Weston, C	1
Krone, W; Müller-Wieland, D	1
Angelin, B; Eggertsen, G; Eriksson, M; Lind, S; Olsson, AG; Rudling, M	1
Findlay, JM; Francis, GA; Hegele, RA; Johnson, RL; Wang, J	1
de Groot, E; Kastelein, JJ; Sager, PT; Veltri, E	1
Endo, M; Harada-Shiba, M; Kato, H; Kusakabe, N; Shoji, T; Tanioka, T; Yamamoto, A	1
Bellocchio, A; Bertolini, S; Bocchi, L; Calandra, S; Cantafora, A; Colangeli, I; Fasano, T; Fresa, R; Pisciotta, L; Sallo, R	1
Kesäniemi, A	1
Padial, LR	1
Greenland, P; Lloyd-Jones, D	1
Curfman, GD; Drazen, JM; Jarcho, JA; Morrissey, S	1
Akdim, F; Bots, ML; de Groot, E; Duivenvoorden, R; Gaudet, D; Kastelein, JJ; Marais, AD; Sijbrands, EJ; Stalenhoef, AF; Stein, EA; Stroes, ES; Trip, MD; Veltri, EP; Visseren, FL; Zwinderman, AH	1
Brown, BG; Taylor, AJ	1
Jehlicka, P; Mayer, O; Racek, J; Siala, K; Stožický, F; Trefil, L; Varvařovská, J	1
Stein, EA	1
Alonso, R; Fernández de Bobadilla, J; Lázaro, P; Mata, N; Mata, P; Méndez, I	1
Jackson, G	1
Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE	1
Bruckert, E; Gagné, C; Gaudet, D	1

Reviews

26 review(s) available for ezetimibe and Hyperlipoproteinemia Type II

Article	Year
Lipid management across Europe in the real-world setting: a rapid evidence review. Current medical research and opinion, 2021, Volume: 37, Issue:12 Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Middle Aged; Treatment Outcome	2021
2022 Consensus statement on the management of familial hypercholesterolemia in Korea. The Korean journal of internal medicine, 2022, Volume: 37, Issue:5 Topics: Adult; Child; Cholesterol, LDL; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Proprotein Convertase 9; Xanthomatosis	2022
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:6 Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Drug Combinations; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Receptors, LDL	2020
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia. Clinical therapeutics, 2021, Volume: 43, Issue:2 Topics: Atherosclerosis; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents	2021
Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. Current atherosclerosis reports, 2021, 05-08, Volume: 23, Issue:6 Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Ezetimibe; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II	2021
Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag. Reviews in cardiovascular medicine, 2018, Volume: 19, Issue:S1 Topics: Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors; Phenotype; Proprotein Convertase 9; Risk Factors; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome	2018
Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis, 2018, Volume: 277 Topics: Anticholesteremic Agents; Benzimidazoles; Biomarkers; Blood Component Removal; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors; Phenotype; Practice Guidelines as Topic; Proprotein Convertase 9; Serine Proteinase Inhibitors; Treatment Outcome	2018
Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment. Current pharmaceutical design, 2018, Volume: 24, Issue:31 Topics: Adolescent; Bile Acids and Salts; Child; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors; Proprotein Convertase 9	2018
[Diagnosis and Treatment of Familial Hypercholesterolemia]. Praxis, 2018, Volume: 107, Issue:24 Topics: Apolipoproteins B; Cardiovascular Diseases; DNA Mutational Analysis; Ezetimibe; Genetic Carrier Screening; Genetic Testing; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors; Proprotein Convertase 9; Receptors, LDL	2018
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Young Adult	2013
[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Orvosi hetilap, 2014, Jan-12, Volume: 155, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2014
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. Internal medicine journal, 2014, Volume: 44, Issue:6 Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL	2014
[Heterozygous familial hypercholesterolemia]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2014, Volume: 42 Suppl 2 Topics: Azetidines; Early Diagnosis; Ezetimibe; Genetic Predisposition to Disease; Genetic Testing; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Niacin	2014
Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis, 2015, Volume: 241, Issue:2 Topics: Anticholesteremic Agents; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Cost-Benefit Analysis; Ezetimibe; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Mass Screening; Mutation; Netherlands; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Risk; Serine Endopeptidases	2015
Recent advances in the pharmacological management of hypercholesterolaemia. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; PCSK9 Inhibitors	2016
Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs, 2016, Volume: 76, Issue:12 Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Risk Factors; Subtilisin	2016
[Up to date lipid lowering treatment]. Orvosi hetilap, 2016, Volume: 157, Issue:31 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors	2016
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2016, Aug-09, Volume: 316, Issue:6 Topics: Adolescent; Advisory Committees; Biomarkers; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mass Screening; Myocardial Infarction; Observational Studies as Topic; Preventive Health Services; Simvastatin; Stroke; United States	2016
Ezetimibe--an update. Drug and therapeutics bulletin, 2009, Volume: 47, Issue:8 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hyperlipoproteinemia Type II; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin	2009
Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory? World review of nutrition and dietetics, 2009, Volume: 100 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vascular health and risk management, 2010, Nov-10, Volume: 6 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Treatment Outcome	2010
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011? Complementary therapies in medicine, 2011, Volume: 19, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Margarine; Micronutrients; Niacin; Phytosterols; Sitosterols; Triglycerides	2011
The place of ezetimibe in clinical practice. Hospital medicine (London, England : 1998), 2003, Volume: 64, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II	2003
[Hyperlipidemia: therapeutic principles in clinical practice]. Medizinische Klinik (Munich, Germany : 1983), 2003, Dec-15, Volume: 98, Issue:12 Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Insulin Resistance; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Risk Factors; Time Factors; Weight Loss	2003
Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials. Fundamental & clinical pharmacology, 2007, Volume: 21 Suppl 2 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Simvastatin; Treatment Outcome	2007
Ezetimibe plus simvastatin cardiovascular outcomes study program. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome	2008

Trials

22 trial(s) available for ezetimibe and Hyperlipoproteinemia Type II

Article	Year
Reduced gut microbial diversity in familial hypercholesterolemia with no effect of omega-3 polyunsaturated fatty acids intervention - a pilot trial. Scandinavian journal of clinical and laboratory investigation, 2022, Volume: 82, Issue:5 Topics: Cholesterol; Cross-Over Studies; Ezetimibe; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Gastrointestinal Microbiome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Pilot Projects; RNA, Ribosomal, 16S	2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. The lancet. Diabetes & endocrinology, 2022, Volume: 10, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Child; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Proprotein Convertase 9; Subtilisins; Treatment Outcome	2022
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). The American journal of cardiology, 2019, 12-15, Volume: 124, Issue:12 Topics: Anticholesteremic Agents; Caproates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; Proprotein Convertase 9; Receptors, LDL; Survival Analysis; Time Factors; Treatment Outcome	2019
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arteriosclerosis, thrombosis, and vascular biology, 2018, Volume: 38, Issue:3 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Receptors, LDL; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult	2018
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Young Adult	2013
Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in health and disease, 2016, Apr-02, Volume: 15 Topics: Adult; Aged; Anticholesteremic Agents; Drug Therapy, Combination; Epichlorohydrin; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Imidazoles; Lipase; Lipoprotein Lipase; Male; Middle Aged; Receptors, LDL; Resins, Synthetic; Rosuvastatin Calcium	2016
Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:12 Topics: Apolipoprotein B-100; Arterial Pressure; Biomarkers; Cardiovascular Diseases; Cross-Over Studies; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Time Factors; Treatment Outcome; Triglycerides; Vascular Stiffness; Western Australia	2016
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment. International journal of cardiology, 2017, 02-01, Volume: 228 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Treatment Outcome	2017
[Therapy of familial hypercholesterolemia with or without ezetimibe]. Der Internist, 2008, Volume: 49, Issue:10 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Carotid Stenosis; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Simvastatin	2008
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. Journal of the American College of Cardiology, 2008, Oct-21, Volume: 52, Issue:17 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Simvastatin; Time Factors; Treatment Outcome	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial). Current atherosclerosis reports, 2009, Volume: 11, Issue:2 Topics: Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Prospective Studies; Simvastatin	2009
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged	2009
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. Journal of lipid research, 2010, Volume: 51, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Male; Middle Aged; Phytosterols; Simvastatin; Sitosterols; Statistics as Topic	2010
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clinical therapeutics, 2010, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Apolipoproteins; Azetidines; Body Mass Index; Cholesterol; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Smoking; Triglycerides; Young Adult	2010
Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. The American journal of cardiology, 2012, Feb-01, Volume: 109, Issue:3 Topics: Aged; Aged, 80 and over; Anion Exchange Resins; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epichlorohydrin; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrimidines; Resins, Synthetic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle Lancet (London, England), 2012, Jul-07, Volume: 380, Issue:9836 Topics: Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome	2012
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibiti Circulation, 2012, Nov-13, Volume: 126, Issue:20 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome	2012
Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis, 2007, Volume: 194, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Serine Endopeptidases	2007
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Apr-03, Volume: 358, Issue:14 Topics: Adult; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Tunica Media; Ultrasonography	2008
Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiological research, 2009, Volume: 58, Issue:2 Topics: Adolescent; Anticholesteremic Agents; Arginine; Azetidines; Biomarkers; Child; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Risk Factors; Ultrasonography; Vitamin B Complex	2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology, 2008, Apr-22, Volume: 51, Issue:16 Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin	2008
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002, May-28, Volume: 105, Issue:21 Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome	2002

Other Studies

88 other study(ies) available for ezetimibe and Hyperlipoproteinemia Type II

Article	Year
LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. International journal of cardiology, 2021, Dec-15, Volume: 345 Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Middle Aged; Proprotein Convertase 9	2021
Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab. Molecular genetics and genomics : MGG, 2022, Volume: 297, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Mutation; Pedigree; Phenotype; Proprotein Convertase 9; Receptors, LDL; Rosuvastatin Calcium	2022
Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid. The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:9 Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Proprotein Convertase 9	2022
Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics. Journal of atherosclerosis and thrombosis, 2023, Oct-01, Volume: 30, Issue:10 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Practice Patterns, Physicians'; Treatment Outcome	2023
LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis. Atherosclerosis, 2023, Volume: 384 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Retrospective Studies; Treatment Outcome	2023
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. European journal of preventive cardiology, 2023, Nov-30, Volume: 30, Issue:17 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Homozygous Familial Hypercholesterolemia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Standard of Care	2023
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation, 2020, 06-02, Volume: 141, Issue:22 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Gene Knockdown Techniques; Genetic Therapy; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Molecular Targeted Therapy; PCSK9 Inhibitors; Pilot Projects; Proof of Concept Study; Proprotein Convertase 9; RNA Interference; RNA, Small Interfering; Treatment Outcome	2020
A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5. Endocrine journal, 2020, Nov-28, Volume: 67, Issue:11 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol; Cholesterol, LDL; Diagnostic Errors; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Loss of Function Mutation; Middle Aged; Phytosterols; Sitosterols; Treatment Failure	2020
Life by the Numbers: Living With Familial Hypercholesterolemia. Circulation. Genomic and precision medicine, 2021, Volume: 14, Issue:1 Topics: Cholesterol; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Proprotein Convertase 9	2021
Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021, 03-10, Volume: 31, Issue:3 Topics: Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation Mediators; Italy; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; PCSK9 Inhibitors; Prospective Studies; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Triglycerides	2021
Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021, 05-06, Volume: 31, Issue:5 Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenotype; Registries; Rosuvastatin Calcium; Simvastatin; Spain; Treatment Outcome	2021
Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting. Acta diabetologica, 2021, Volume: 58, Issue:7 Topics: Aged; Anticholesteremic Agents; Blood Flow Velocity; Cholesterol, HDL; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Italy; Leukocyte Count; Lipid Metabolism; Male; Middle Aged; Monocytes; PCSK9 Inhibitors; Prospective Studies; Pulse Wave Analysis	2021
Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Journal of atherosclerosis and thrombosis, 2022, May-01, Volume: 29, Issue:5 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Japan; Male; Probucol; Xanthomatosis	2022
Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. Internal medicine journal, 2021, Volume: 51, Issue:5 Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Physicians; Proprotein Convertase 9	2021
Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry. PloS one, 2021, Volume: 16, Issue:6 Topics: Bahrain; Cholesterol, LDL; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Kuwait; Male; Middle Aged; Oman; Prevalence; Registries; Risk Factors; Saudi Arabia; Serine Endopeptidases; United Arab Emirates	2021
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. International journal of molecular sciences, 2021, Jul-03, Volume: 22, Issue:13 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Italy; Lipoproteins, LDL; Male; Middle Aged; NADPH Oxidase 2; PCSK9 Inhibitors; Platelet Activation; Proprotein Convertase 9	2021
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. European journal of preventive cardiology, 2017, Volume: 24, Issue:10 Topics: Age of Onset; Anticholesteremic Agents; Apolipoprotein B-100; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; DNA Mutational Analysis; Ezetimibe; Genetic Association Studies; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Italy; Mutation; Mutation Rate; Phenotype; Plaque, Atherosclerotic; Prevalence; Proprotein Convertase 9; Receptors, LDL; Retrospective Studies; Risk Factors; Treatment Outcome	2017
Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. The Canadian journal of cardiology, 2017, Volume: 33, Issue:5 Topics: Aged; Anticholesteremic Agents; Aorta; Aortic Diseases; Calcium; Cholesterol, LDL; Ezetimibe; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Receptors, LDL; Tomography, X-Ray Computed; Vascular Calcification	2017
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition? Atherosclerosis, 2017, Volume: 262 Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Eligibility Determination; Ezetimibe; Female; Guideline Adherence; Health Services Accessibility; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Registries; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Spain; Time Factors; Treatment Outcome	2017
Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. BMJ open, 2017, 07-02, Volume: 7, Issue:6 Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Ezetimibe; Fibric Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Incidence; Ischemic Attack, Transient; Japan; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Observational Studies as Topic; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Prospective Studies; Registries; Research Design; Risk Factors; Stroke	2017
Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease. Circulation journal : official journal of the Japanese Circulation Society, 2017, 12-25, Volume: 82, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Disease Management; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Risk Factors; Treatment Outcome	2017
Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical chemistry, 2018, Volume: 64, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Apolipoprotein B-100; Child; Cholesterol, LDL; Cohort Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Proprotein Convertase 9; Receptors, LDL; Young Adult	2018
Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis. Supplements, 2017, Volume: 30 Topics: Adult; Aged; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Diet, Fat-Restricted; Dietary Supplements; Ezetimibe; Female; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Monascus; Mutation; Phenotype; Time Factors; Treatment Outcome; Young Adult	2017
Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:12 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Retrospective Studies; Treatment Outcome	2017
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. The American journal of cardiology, 2018, 05-15, Volume: 121, Issue:10 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Retrospective Studies	2018
Complex disease management of pregnant young patient with familial hypercholesterolaemia complicated by coronary artery disease and cerebrovascular disease. Cardiovascular revascularization medicine : including molecular interventions, 2018, Volume: 19, Issue:8S Topics: Adult; Anticholesteremic Agents; Cerebrovascular Disorders; Cholesterol, LDL; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Echocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant, Newborn; Magnetic Resonance Angiography; Magnetic Resonance Imaging, Cine; Pregnancy; Pregnancy Complications, Cardiovascular	2018
Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. Atherosclerosis, 2018, Volume: 277 Topics: Adult; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Guideline Adherence; Heredity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pedigree; Phenotype; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prevalence; Retrospective Studies; Risk Assessment; Risk Factors; Slovakia; Time Factors; Treatment Outcome	2018
LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. Atherosclerosis, 2018, Volume: 277 Topics: Adult; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heredity; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Pedigree; Phenotype; Prevalence; Proprotein Convertase 9; Retrospective Studies; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; South Africa; Time Factors; Treatment Outcome	2018
Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis, 2018, Volume: 277 Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Czech Republic; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Proprotein Convertase 9; Registries; Retrospective Studies; Risk Assessment; Serine Proteinase Inhibitors; Slovakia; Time Factors; Treatment Outcome	2018
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle. Atherosclerosis, 2018, Volume: 277 Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cholesterol, LDL; Early Diagnosis; Ezetimibe; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proprotein Convertase 9; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Uzbekistan	2018
Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report. Medicine, 2018, Volume: 97, Issue:42 Topics: Adolescent; Anticholesteremic Agents; Aspirin; Coronary Disease; Ezetimibe; Female; Heart Failure; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mutation; Myocardial Ischemia; Platelet Aggregation Inhibitors; Receptors, LDL; Xanthogranuloma, Juvenile	2018
Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia medica, 2018, Sep-01, Volume: 60, Issue:3 Topics: Bulgaria; Cholesterol, LDL; Disease Management; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Retrospective Studies; Risk; Treatment Outcome	2018
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation. Internal medicine (Tokyo, Japan), 2018, Volume: 57, Issue:24 Topics: Acute Coronary Syndrome; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Plaque, Amyloid; Proprotein Convertase 9; Receptors, LDL; Rosuvastatin Calcium	2018
Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene. Atherosclerosis, 2019, Volume: 282 Topics: Adult; Alleles; Apolipoproteins E; Case-Control Studies; Cholesterol, LDL; Ezetimibe; Female; Gene Deletion; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Leucine; Lipid Metabolism; Male; Middle Aged; Mutation; Receptors, LDL; Retrospective Studies	2019
Hypercholesterolemia Among Premature Infarcts: Time to Start the Clock of Familial Hypercholesterolemia Assessment. Journal of the American College of Cardiology, 2019, 05-21, Volume: 73, Issue:19 Topics: Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Infarction; Myocardial Infarction; Proprotein Convertase 9; Young Adult	2019
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2014, Volume: 233, Issue:1 Topics: Adult; Aged; Atorvastatin; Azetidines; Brazil; Cholesterol, LDL; Ezetimibe; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Pyrroles; Receptors, LDL	2014
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Adult; Aged; Anthropometry; Anticholesteremic Agents; Azetidines; Biomarkers; Cells, Cultured; Cholesterol, LDL; Culture Media; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Serum; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; Tumor Necrosis Factor-alpha	2014
Evolocumab (AMG 145) for primary hypercholesterolemia. Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2015
Long-term atorvastatin-ezetimibe-probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood. Cardiology in the young, 2016, Volume: 26, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Probucol; Time Factors	2016
Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. Current vascular pharmacology, 2015, Volume: 13, Issue:6 Topics: Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Middle East; Plasma Exchange; Practice Guidelines as Topic; Prevalence; Risk Factors	2015
Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe. Atherosclerosis, 2016, Volume: 246 Topics: Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; DNA Mutational Analysis; Down-Regulation; Ezetimibe; Female; Genetic Markers; Genotype; HEK293 Cells; Humans; Hyperlipoproteinemia Type II; Male; Membrane Proteins; Membrane Transport Proteins; Models, Molecular; Molecular Dynamics Simulation; Mutation; Phenotype; Protein Binding; Protein Conformation; Proteomics; Transfection; Treatment Outcome	2016
Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2016, Mar-22, Volume: 67, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Registries; Rosuvastatin Calcium	2016
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. Journal of the American College of Cardiology, 2016, Mar-22, Volume: 67, Issue:11 Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Registries; Rosuvastatin Calcium; Spain; Time Factors; Treatment Outcome; Young Adult	2016
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:12 Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Blood Component Removal; Codon, Terminator; Combined Modality Therapy; Coronary Disease; DNA Mutational Analysis; Ezetimibe; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Myocardial Revascularization; Receptors, LDL; Simvastatin	2016
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA, 2016, Aug-16, Volume: 316, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Quality-Adjusted Life Years; Serine Endopeptidases; Uncertainty; United States	2016
A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents. Journal of pediatric endocrinology & metabolism : JPEM, 2016, Nov-01, Volume: 29, Issue:11 Topics: Adolescent; Anticholesteremic Agents; Argentina; Cardiovascular Diseases; Child; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Outpatient Clinics, Hospital; Practice Guidelines as Topic; Prospective Studies; Risk Factors; Severity of Illness Index	2016
The ENHANCE study and marketing ezetimibe. JAMA, 2008, Jun-18, Volume: 299, Issue:23 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hyperlipoproteinemia Type II	2008
[Commentary to the article: Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43 ]. Kardiologia polska, 2008, Volume: 66, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome	2008
Enhanced hype. The American journal of cardiology, 2008, Aug-01, Volume: 102, Issue:3 Topics: Administration, Inhalation; Anticholesteremic Agents; Azetidines; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Information Dissemination; Simvastatin; United States	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media	2008
Intensive lipid intervention in the post-ENHANCE era. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Reproducibility of Results; Simvastatin; Tunica Intima; Tunica Media	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Gene Expression Regulation; Humans; Hyperlipoproteinemia Type II; Intestinal Absorption; Membrane Transport Proteins; Mice	2008
Therapy and clinical trials. Current opinion in lipidology, 2008, Volume: 19, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic	2008
Is carotid intima-media thickness a reliable clinical predictor? Mayo Clinic proceedings, 2008, Volume: 83, Issue:11 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media	2008
A new method for measurement of total plasma PCSK9: clinical applications. Journal of lipid research, 2010, Volume: 51, Issue:1 Topics: Antibodies; Azetidines; Blood Glucose; Cell Line; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Triglycerides	2010
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Transactions of the American Clinical and Climatological Association, 2009, Volume: 120 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; Case-Control Studies; Ezetimibe; Female; Genetic Variation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; RNA, Messenger; Serine Endopeptidases; Young Adult	2009
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis, 2010, Volume: 209, Issue:1 Topics: Adult; Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Drug Monitoring; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Netherlands	2010
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Current medical research and opinion, 2010, Volume: 26, Issue:3 Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Costs and Cost Analysis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Theoretical; Risk Factors	2010
Homozygous familial hypercholesterolaemia and treatment by LDL apheresis. The New Zealand medical journal, 2010, Jul-30, Volume: 123, Issue:1319 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Blood Component Removal; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hyperlipoproteinemia Type II; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Heterozygous familial hypercholesterolemia case study. Journal of the American Academy of Nurse Practitioners, 2010, Volume: 22, Issue:10 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Life Style; Male; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States	2010
Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. The American journal of cardiology, 2011, Jul-15, Volume: 108, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Niacin; Ohio; Pyrimidines; Registries; Rosuvastatin Calcium; Sulfonamides; Vitamin B Complex; Young Adult	2011
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids in health and disease, 2011, Jun-10, Volume: 10 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult	2011
Management of familial hypercholesterolaemia in children and adolescents. Journal of paediatrics and child health, 2012, Volume: 48, Issue:2 Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Azetidines; Child; Child, Preschool; Cholesterol, LDL; Disease Management; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II	2012
[Use of ezetimibe in the treatment of familial hypercholesterolemia in children and adolescents]. Anales de pediatria (Barcelona, Spain : 2003), 2012, Volume: 77, Issue:1 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Child; Child, Preschool; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Retrospective Studies	2012
[Genetic principles of food related problems--familial hypercholesterolaemia]. Journal de pharmacie de Belgique, 2012, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II	2012
Inhibition of PCSK9 in familial hypercholesterolaemia. Lancet (London, England), 2012, Jul-07, Volume: 380, Issue:9836 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male	2012
Autosomal recessive hypercholesterolaemia in a Morrocan family due to a mutation of the G266C LDL receptor. BMJ case reports, 2012, May-23, Volume: 2012 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Consanguinity; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Morocco; Mutation; Receptors, LDL; Young Adult	2012
Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk. BMJ case reports, 2012, Jul-17, Volume: 2012 Topics: Acromegaly; Adenoma; Adult; Azetidines; Cardiovascular Diseases; Coinfection; Ezetimibe; Female; Fluorobenzenes; Hepatitis C; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Magnetic Resonance Imaging; Pituitary Neoplasms; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2012
First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Angiology, 2013, Volume: 64, Issue:4 Topics: Achilles Tendon; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Blood Component Removal; Carotid Artery Diseases; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; DNA Mutational Analysis; Drug Combinations; Exons; Eye Diseases; Ezetimibe; Female; Fluorobenzenes; Frameshift Mutation; Genetic Predisposition to Disease; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Oman; Pedigree; Phenotype; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sequence Deletion; Sulfonamides; Treatment Outcome; Triglycerides; Xanthomatosis	2013
Familial hypercholesterolaemia in children and adolescents: a new paediatric model of care. Journal of paediatrics and child health, 2013, Volume: 49, Issue:4 Topics: Adolescent; Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Child; Congenital Abnormalities; Coronary Stenosis; Disease Progression; Early Diagnosis; Ezetimibe; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Standard of Care	2013
[Antibodies in addition to statin therapy lowers LDL cholesterol]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:36 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Multicenter Studies as Topic; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2012
[Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"]. MMW Fortschritte der Medizin, 2003, May-15, Volume: 145, Issue:20 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin	2003
Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. Journal of internal medicine, 2004, Volume: 256, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Child; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pedigree; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Xanthomatosis	2004
Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Feb-15, Volume: 172, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Brain Diseases; Cholesterol; Cholesterol, LDL; Conjunctival Diseases; Drug Therapy, Combination; Edema; Ezetimibe; Female; Granuloma, Foreign-Body; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Middle Aged; Ophthalmic Solutions; Point Mutation; Vasodilation	2005
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENH American heart journal, 2005, Volume: 149, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography	2005
The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis, 2006, Volume: 186, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Blood Component Removal; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Follow-Up Studies; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Treatment Outcome; Triglycerides	2006
In brief: Zetia and Vytorin: the ENHANCE study. The Medical letter on drugs and therapeutics, 2008, Jan-28, Volume: 50, Issue:1278 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, LDL; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2008
Critical lessons from the ENHANCE trial. JAMA, 2008, Feb-27, Volume: 299, Issue:8 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Conflict of Interest; Data Interpretation, Statistical; Drug Approval; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Mass Media; Randomized Controlled Trials as Topic; Simvastatin; Ultrasonography	2008
Cholesterol lowering and ezetimibe. The New England journal of medicine, 2008, Apr-03, Volume: 358, Issue:14 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Triglycerides; Tunica Intima; Tunica Media	2008
Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? The New England journal of medicine, 2008, Apr-03, Volume: 358, Issue:14 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Tunica Media	2008
After ENHANCE: is more LDL cholesterol lowering even better? Clinical chemistry, 2008, Volume: 54, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin	2008
[Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy]. Revista espanola de cardiologia, 2008, Volume: 61, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Models, Economic; Pyrroles	2008
ENHANCE: food for the ostriches. International journal of clinical practice, 2008, Volume: 62, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin	2008